MLICM
SPRY icon

Metropolitan Life Insurance Company (MetLife)’s ARS Pharmaceuticals SPRY Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,495
Closed -$15.3K – 1824
2024
Q1 		$15.3K Buy
1,495
+67
+5% +$500 ﹤0.01% 1979
2023
Q4 		$7.83K Hold
1,428
– – ﹤0.01% 2248
2023
Q3 		$5.4K Hold
1,428
– – ﹤0.01% 2387
2023
Q2 		$9.57K Buy
+1,428
New +$9.53K ﹤0.01% 2320
2021
Q4 		– Sell
-6,383
Closed -$63.7K – 2825
2021
Q3 		$63.7K Buy
+6,383
New +$157K ﹤0.01% 2727
2021
Q2 		– Sell
-4,038
Closed -$176K – 2861
2021
Q1 		$176K Buy
+4,038
New +$191K ﹤0.01% 2107

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SPRY Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of ARS Pharmaceuticals (SPRY) in Q2 2024, closing a stake of 1,495 shares — an estimated $15.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SPRY in Q1 2021 and held it in 6 quarters. The position peaked at $176K in Q1 2021. 115 funds tracked by Wall St. Rank hold SPRY as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining ARS Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,495 ARS Pharmaceuticals shares in Q2 2024, an estimated $15.3K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s ARS Pharmaceuticals position peaked at $176K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.